To control for any variability in signature discovery caused by the molecular breast cancer subtypes, we matched both ER and HER2 status of 22/24 samples used for training (Fig. 1a, left, see highlighted ER and HER2 scores). This evidence concerns the gene ESR1 and breast carcinoma.